VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Thursday, January 8, 2026
Stock Comparison
Eli Lilly and Company vs Marsh & McLennan Companies, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Eli Lilly and Company
LLY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.
View LLY analysisMarsh & McLennan Companies, Inc.
MMC · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Marsh & McLennan Companies, Inc.'s moat claims, evidence, and risks.
View MMC analysisComparison highlights
- Moat score gap: Eli Lilly and Company leads (66 / 100 vs 65 / 100 for Marsh & McLennan Companies, Inc.).
- Segment focus: Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health); Marsh & McLennan Companies, Inc. has 2 segments (62.8% in Risk and Insurance Services).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Eli Lilly and Company has 5 moat types across 2 domains; Marsh & McLennan Companies, Inc. has 5 across 3.
Primary market context
Eli Lilly and Company
Cardiometabolic Health
Branded cardiometabolic pharmaceuticals (type 2 diabetes, obesity, and related metabolic/cardiovascular conditions; especially incretin therapies)
Global
Patients via prescribers; payers/PBMs; wholesaler & pharmacy channels
Drug developer, manufacturer, and marketer
65.5%
Marsh & McLennan Companies, Inc.
Risk and Insurance Services
Insurance brokerage, risk advisory, and reinsurance brokerage/services
Global
Enterprises, public entities, associations, and individuals (via broker/agent channels)
Intermediary + advisor (insurance/reinsurance market intermediary)
62.8%
Side-by-side metrics
Moat coverage
Shared moat types
Eli Lilly and Company strengths
Marsh & McLennan Companies, Inc. strengths
Segment mix
Eli Lilly and Company segments
Full profile >Cardiometabolic Health
Oligopoly
Oncology
Competitive
Immunology
Competitive
Neuroscience
Competitive
Other
Competitive
Marsh & McLennan Companies, Inc. segments
Full profile >Risk and Insurance Services
Oligopoly
Consulting
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.